BioSpace News Archive

Sphere Fluidics announced its involvement in 3DSecret, a four-year research project funded through the European Innovation Council’s Pathfinder Open 2022, established under Horizon Europe, the EU’s key funding program for research and innovation.

Regenative Labs, a leading human cell, tissue, cellular and tissue-based products manufacturer, has partnered with Dr. Michael Lavor to conduct a prospective study on the efficacy and safety of using umbilical cord tissue allografts for Charcot foot.

Theravance Biopharma, Inc. will report its first quarter 2023 financial results and provide a business update after market close on Monday, May 8, 2023.

Axonics, Inc., a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, announced the acquisition of a lead placement solution from Radian, LLC that complements Axonics’ existing sacral neuromodulation offering.

WuXi AppTec is pleased to announce its financial results for the first quarter ending March 31, 2023.

Simcere Pharmaceutical disclosed the latest progress on the company’s R&D and business operation on its first Investor Day themed “Focusing on more effective new products with differentiated clinical value” in Hong Kong.

ImmunoGen, Inc., a leader in the expanding field of antibody-drug conjugates for the treatment of cancer, announced that Isabel Kalofonos has been appointed Senior Vice President and Chief Commercial Officer.

BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a clinical stage company focused on stem cell-based therapies, today announced that it has completed enrollment for the safety run-in component of its Phase 2 clinical study of BRTX-100 targeting patients suffering from chronic lumbar disc disease (cLDD).

YourBio Health, Inc, the developers of the world’s first virtually painless push-button blood collection device, announced today that TAP® Micro Select received 510(k) Medical Device clearance from the U.S. Food and Drug Administration (FDA).

Despite the promise of new medications that promote cancer cell death in people with acute myeloid leukemia, leukemic cells often adopt features that let them evade the drugs’ effects within a year.